View in EDS HTML Full Text PDF Full Text

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.

Saved in:
Bibliographic Details
Title: Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.
Authors: Diya, Oyeniyi1 (AUTHOR), Gayed, Juleen1 (AUTHOR) juleen.gayed@pfizer.com, Lowry, Francine S.2 (AUTHOR), Ma, Hua2 (AUTHOR), Bangad, Vishva2 (AUTHOR), Mensa, Federico3 (AUTHOR), Zou, Jing4 (AUTHOR), Xie, Xuping4 (AUTHOR), Hu, Yanping4 (AUTHOR), Cutler, Mark5 (AUTHOR), Belanger, Todd5 (AUTHOR), Cooper, David5 (AUTHOR), Xu, Xia2 (AUTHOR), Mogg, Robin2 (AUTHOR), Türeci, Özlem3 (AUTHOR), Şahin, Uǧur3 (AUTHOR), Swanson, Kena A.5 (AUTHOR), Modjarrad, Kayvon5 (AUTHOR), Anderson, Annaliesa S.5 (AUTHOR), Gurtman, Alejandra5 (AUTHOR)
Source: Infectious Diseases & Therapy. Aug2025, Vol. 14 Issue 8, p1973-1987. 15p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938229
DOI:10.1007/s40121-025-01185-4